COG 133 (TFA)

COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM[1][2].

Product Specifications

CAS Number

[2828432-37-5]

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Apolipoprotein; nAChR

Type

Peptides

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cog-133-tfa.html

Purity

99.89

Solubility

H2O : 25 mg/mL (ultrasonic)

Smiles

OC(C(F)(F)F)=O.CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CO)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@@H](NC(C)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)CC1=CN=CN1)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]

Molecular Formula

C99H182F3N37O21.xC2HF3O2

Molecular Weight

2283.78 (free base)

Precautions

H302, H315, H319, H335

References & Citations

[1]Orleâncio Gomes R Azevedo, et al. Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol. 2012 Jul 13;12:35.|[2]Elaine A Gay, et al. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. J Pharmacol Exp Ther. 2006 Feb;316 (2) :835-42.|[3]Huachun Cui, et al. Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insight. 2020 Mar 12;5 (5) :e134539.